Literature DB >> 11412141

Skeletal muscle training in chronic heart failure.

M F Piepoli1, A C Scott, A Capucci, A J Coats.   

Abstract

Patients with heart failure are limited in their ability to tolerate exercise. Recent research has suggested that this limitation cannot be entirely attributed to cardiac or lung impairment but rather that changes in peripheral muscles may play an important role. There are objective similarities between heart failure and muscular deconditioning. Deficiencies in peripheral blood flow and skeletal muscle function, morphology, metabolism and function are present in both conditions. Moreover, an exaggerated activity of the receptors sensitive to exercise-derived metabolic signals (muscle ergoreceptors and peripheral and central chemoreceptors) leads to early and profound exercise-induced fatigue and dyspnoea. These muscle afferents contribute to the ventilatory, haemodynamic and autonomic responses to exercise both in physiological and pathological conditions, including chronic heart failure. Against this background, a skeletal muscle origin of symptoms in heart failure has been proposed. The protective effects of physical training have been described in many recent studies: training improves ventilatory control, skeletal muscle metabolism and autonomic nervous system activity. The exercise training appears to induce its beneficial effects on skeletal muscle both directly (on muscle function, histological and biochemical features) and indirectly (by reducing the activation of the muscle afferents). The metabolic mediators of these muscle afferents may become a potential target in the future therapy of heart failure symptoms.

Entities:  

Mesh:

Year:  2001        PMID: 11412141     DOI: 10.1046/j.1365-201x.2001.00831.x

Source DB:  PubMed          Journal:  Acta Physiol Scand        ISSN: 0001-6772


  10 in total

Review 1.  Testosterone and heart failure.

Authors:  Maurizio Volterrani; Giuseppe Rosano; Ferdinando Iellamo
Journal:  Endocrine       Date:  2012-06-24       Impact factor: 3.633

Review 2.  Invited review: activity-induced angiogenesis.

Authors:  Stuart Egginton
Journal:  Pflugers Arch       Date:  2008-08-13       Impact factor: 3.657

3.  Eccentric exercise in patients with chronic health conditions: a systematic review.

Authors:  Marc Roig; Babak Shadgan; W Darlene Reid
Journal:  Physiother Can       Date:  2008-10-10       Impact factor: 1.037

Review 4.  Central neural control of sympathetic nerve activity in heart failure following exercise training.

Authors:  Kaushik P Patel; Hong Zheng
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-11-18       Impact factor: 4.733

Review 5.  Testosterone deficiency and exercise intolerance in heart failure: treatment implications.

Authors:  Ferdinando Iellamo; Giuseppe Rosano; Maurizio Volterrani
Journal:  Curr Heart Fail Rep       Date:  2010-06

6.  Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment.

Authors:  B Shariat-Madar; D Kolte; A Verlangieri; Z Shariat-Madar
Journal:  Diabetes Metab Syndr Obes       Date:  2010-04       Impact factor: 3.168

7.  Central and peripheral testosterone effects in men with heart failure: An approach for cardiovascular research.

Authors:  Željko Bušić; Viktor Čulić
Journal:  World J Cardiol       Date:  2015-09-26

8.  Response to cardiac resynchronization therapy: the muscular metabolic pathway.

Authors:  Jérémie Jaussaud; Pierre Blanc; Pierre Bordachar; Raymond Roudaut; Hervé Douard
Journal:  Cardiol Res Pract       Date:  2010-12-20       Impact factor: 1.866

9.  Resistance training improves hemodynamic function, collagen deposition and inflammatory profiles: experimental model of heart failure.

Authors:  Jadson P Alves; Ramiro B Nunes; Giuseppe P Stefani; Pedro Dal Lago
Journal:  PLoS One       Date:  2014-10-23       Impact factor: 3.240

Review 10.  Aerobic Exercise and Pharmacological Therapies for Skeletal Myopathy in Heart Failure: Similarities and Differences.

Authors:  Aline V Bacurau; Telma F Cunha; Rodrigo W Souza; Vanessa A Voltarelli; Daniele Gabriel-Costa; Patricia C Brum
Journal:  Oxid Med Cell Longev       Date:  2016-01-19       Impact factor: 6.543

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.